Editor---In a minority of coronavirus disease 2019 (COVID-19) patients, severe acute hypoxaemic respiratory failure (AHRF) necessitates admission to an ICU for invasive mechanical ventilation with an associated mortality of \>50%.[@bib1], [@bib2], [@bib3] Published cohorts suggest that noninvasive ventilation is a commonly used intervention in COVID-19-related AHRF[@bib4] ^,^ [@bib5] although no formal evaluation has been reported in the setting of a clinical trial. It is uncertain whether noninvasive ventilation is beneficial or harmful for patients with COVID-19. Here, we report a single centre experience of the role of noninvasive ventilation in patients with respiratory failure associated with COVID-19.

We report an evaluation of the use of ventilatory support in a single academic medical centre (University Hospital Southampton NHS Foundation Trust) during the early phases of the COVID-19 pandemic within the UK. Ethical approval was obtained as part of the REACT observational study of COVID-19 (a longitudinal cohort study to facilitate better understanding and management of severe acute respiratory syndrome coronavirus 2 \[SARS-CoV-2\] from admission to discharge across all levels of care): REC Reference; 17/NW/0632, SRB Reference Number; SRB0025. Informed consent was waived because of the study design. Consecutive patients diagnosed with COVID-19 based on laboratory reverse transcriptase polymerase chain reaction (RT--PCR) tests and with associated AHRF were assessed from hospital admission to establish suitability for invasive mechanical ventilation, noninvasive ventilation, or both in the event of severe respiratory failure. Indications for escalation of care to noninvasive ventilation/invasive mechanical ventilation were based on respiratory distress, gas exchange, other organ dysfunction, and the rate of change in their clinical condition. Patients who were candidates for escalation to invasive mechanical ventilation were admitted to the general ICU (Cohort 1). Patients in whom noninvasive ventilation was defined as the ceiling of ventilation care were admitted to a Level 2 area (Cohort 2). Data were collected from existing electronic hospital records, from the index patient (March 6, 2020) until 16.00 on May 14, 2020. For descriptive statistics, data were presented as median (25th--75th centiles) as variables were found to be non-normally distributed when assessed by the Kolmogorov--Smirnov test. A comparison of proportions was performed using the χ^2^ test. Unadjusted univariate logistic regression was performed to obtain non-adjusted odds ratios and 95% confidence intervals for important variables.

A total of 586 confirmed COVID-19-positive patients were hospitalised during the study period, of whom 103 (17.6%) required noninvasive ventilation or invasive mechanical ventilation. Of these, 79 were admitted to the ICU to receive noninvasive ventilation or invasive mechanical ventilation (Cohort 1), and 24 were admitted to a separate Level 2 area for noninvasive ventilation support as a ceiling of ventilatory care (Cohort 2). Cohort 2 patients were older (median age 67 yr), more frail (median Rockwood clinical frailty scale of 6),6 had more comorbidities (median Charlson comorbidity index of 4),7 and were more hypoxic when care was escalated to noninvasive ventilation ([Table 1](#tbl1){ref-type="table"} ).Table 1Patient characteristics and outcomes of all patients who received noninvasive and invasive ventilation. Data are presented as median (25th--75th centiles). All variables and scoring were performed at the time of the ICU admission. APACHE II, Acute Physiology and Chronic Health Evaluation II; ECMO, extracorporeal membrane oxygenation; IMV, invasive mechanical ventilation; INR, international normalised ratio; NIV, noninvasive ventilation; P~a~O~2~/FiO~2~, partial pressure of arterial oxygen to fraction of inspired oxygen ratio; SOFA, sequential organ failure assessment.Table 1Patient characteristics and outcomesCohort 1 NIV only group (*n*=31)Cohort 1 NIV+IMV group (*n*=27)Cohort 1 IMV only group (*n*=21)Cohort 2 NIV ceiling group (*n*=24)Age (yr)50 (45--60)57 (50--64)61 (18--65)66 (54--72)Female:Male1:21:0.81:3.21:1.4Symptomatic days before hospitalisation7 (6--10)9 (6.5--13)5 (3--10)4 (3--8)Rockwood clinical frailty scale[@bib6]2 (1--2)2 (1--2.5)2 (2--3)6 (5--7)Charlson comorbidity index[@bib7]1 (0--2.5)2 (1--3)3 (1--3)4 (3--7)BMI\>30 kg m^−2^ (%)45412953APACHE II11 (8--12.5)18 (13.0--24.5)22 (15--25)18 (16--20)SOFA score3 (4--3)4 (3--6)6 (4--8)5 (4.5--6)Worse P~a~O~2~/FiO~2~ ratio at 24 h17 (14.3--20.4)13.9 (12.8--16.8)15.3 (12.7--18.1)10.1 (8.2--13.9)Time (h) from hospitalisation to **noninvasive ventilation** initiation or intubation18 (5--54)1 (0--13)1 (0--7)26 (8--94)Total noninvasive ventilation time (h)72 (41--132)17 (4--31)N/A44 (18--103)**Biochemical markers**Creatinine (mM)67 (60--90)60 (48--91)89 (74--142)75 (57--125)Bilirubin (mM)11 (9--12.5)13 (9--18)9 (7--16)11 (8--19)White cell count (10^9^ L^−1^)6.3 (5.3--10.8)7.9 (5.7--13.4)10.6 (8.1--12.6)7 (4.6--9.9)Lymphocytes (10^9^ L^−1^)1 (0.8--1.4)0.8 (0.6--1.0)0.7 (0.6--1.1)0.9 (0.5--1.0)C-reactive protein (mg L^−1^)120 (91--164)158 (113--220)179 (154--276)118 (45--160)INR1.2 (1.1--1.2)1.2 (1.1--1.3)1.2 (1.1--1.4)1.2 (1.1--1.3)Ferritin (mg L^−1^)1093 (451--2243)1014 (542--1380)754 (609--965)326 (111--993)Lactate dehydrogenase (U L^−1^)888 (695--1332)900 (752--1179)1607 (1186--1884)830 (488--1192)Troponin (ng L^−1^)9 (6--15)13 (8--37)64 (27--249)18 (6--102)D-Dimer (mg L^−1^)420 (263--655)540 (333--1057)1677 (682--2884)635 (364--1029)Creatine kinase (U L^−1^)242 (94--412)109 (83--242)247 (116--420)91 (38--235)**Outcome (*n* \[%\])**•Died0 (0)3 (11.1)6 (28.6)20 (83.3)•Home29 (93.5)8 (29.6)8 (38.1)4 (16.7)•Hospitalised (ICU)2 (6.5)9 (33.3)5 (23.8)0 (0)•Hospitalised (ward)0 (0)5 (18.5)2 (9.5)0 (0)•Transferred for ECMO0 (0)2 (7.4)0 (0)0 (0)

Among Cohort 1 patients, 58/79 (73%) had an initial trial of noninvasive ventilation whilst 21/79 (27%) underwent immediate tracheal intubation (Group IMV alone). Among those patients who had an initial trial of noninvasive ventilation, 27/58 progressed to invasive mechanical ventilation (Group NIV+IMV) whereas 31/58 did not require subsequent invasive mechanical ventilation (Group NIV alone). Of note, 29/31 (94%) patients in Group NIV alone were discharged from hospital alive with the remaining 2/31 (6%) being alive in the ICU at the time of data collection. Of Cohort 2 patients, 4/24 (17%) were discharged from hospital alive whereas 20/24 (83%) died in hospital. In Group NIV+IMV, the median time to invasive mechanical ventilation was 17 h (4--31) and 55% failed within the first 24 h. For Group NIV alone, the median noninvasive ventilation duration was 3 days. The median age for patients in Group NIV alone was 50 yr compared with 57 yr in Group NIV+IMV. The clinical frailty scale, Charlson comorbidity index, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and sequential organ failure assessment (SOFA) score were similar between these two groups.

The only variable associated with risk of intubation was the admission SOFA score. In all patients who underwent a trial of noninvasive ventilation (Group NIV alone and Group NIV+IMV), univariate unadjusted logistic regression analysis showed increased SOFA scores on admission were associated with increased risk of tracheal intubation (odds ratio 2.4, 95% confidence interval 1.34--4.38, *P*\<0.0001). Among the patients eligible for escalation to invasive mechanical ventilation, the overall mortality was 9/61 (14%) patients with completed ICU episodes and 9/79 (11%) of all admitted patients including those remaining in the ICU. Overall, 23 patients (30%) remained hospitalised either in the ICU (20%) or on medical wards (10%), and 45 patients (57%) had been successfully discharged home. Two patients were transferred to another tertiary hospital for extracorporeal membrane oxygenation. Substantially higher mortality (83%) was noted among those patients who received noninvasive ventilation as ceiling of care.

Comparisons with published national critical care data for England, Wales, and Northern Ireland from the Intensive Care National Audit and Research Centre (ICNARC) provide interesting context to our data. It is important to emphasise that such comparisons are limited by the absence of comprehensive matching of the characteristics of our patients with those within the ICNARC dataset. APACHE-II and PaO2/FiO2 ratios for Cohort 1 (eligible for escalation to invasive mechanical ventilation) were similar to the ICNARC cohort. However, the use of basic respiratory support (noninvasive ventilation) was more common (73.4% for Cohort 1 *vs* 56.7% ICNARC).1 In comparison with ICNARC mortality from completed episodes (discharged from hospital or dead) (3139/6860; 45.8%), there was a smaller proportion of deaths in all groups except for Cohort 2 (noninvasive ventilation as limit of ventilatory care): overall mortality 29/85 (34.1%); Cohort 1 mortality 9/61 (14.6%).[@bib1]

Despite the widespread use of noninvasive ventilation for the treatment of AHRF and acute respiratory distress syndrome, its utility in COVID-19 lung disease remains controversial.[@bib4] ^,^ [@bib5] ^,^ [@bib8] We report on 103 critically-ill patients with COVID-19 and moderate--severe hypoxaemic respiratory failure, including 24 patients who were offered noninvasive ventilation as a ceiling of ventilatory care. More than half of the patients eligible for escalation to invasive mechanical ventilation tolerated noninvasive ventilation well and avoided tracheal intubation at any time. Unsurprisingly, the mortality and clinical outcome of these patients were better than those patients who were subsequently intubated. In conclusion, noninvasive ventilation is a safe, feasible, and useful ventilatory strategy that may avoid the complications of tracheal intubation and ventilation in selected patients with COVID-19-associated respiratory failure. Our data from a single centre suggest that noninvasive ventilation has a role in the management of COVID-19-associated respiratory failure, but clarification of the nature of this role await the results of large RCTs. Patient selection, defining appropriate limits of care, and effective team working between critical care and respiratory specialists are important in the effective delivery of an integrated clinical ventilation strategy for COVID-19-associated respiratory failure.
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